Nilotinib is a new type of targeted oncology drug, belongs to tyrosine kinase inhibitor, used for the treatment of imatinib-resistant chronic granulocytic leukemia patients, the efficacy is remarkable.Nilotinib is improved from the molecular structure of imatinib, which has stronger selectivity for BCR-ABL kinase activity, and its inhibitory effect on tyrosine kinase is 30 times stronger than that of imatinib, and it can inhibit the kinase activity of imatinib-resistant BCR-ABL mutant, and inhibit the generation of cancer cells containing abnormal chromosomes.It also inhibits KIT and PDGFR kinase activity.